Liang C, Peyman G A, Conway M D, Woltering E A
LSU Eye Center, New Orleans, LA 70112-2234, USA.
Can J Ophthalmol. 1997 Jun;32(4):229-32.
To evaluate the ocular toxicity of intravitreous octreotide.
New Zealand white rabbits weighing approximately 2 kg were given 5 mg (group 1, two eyes), 2 mg (group 2, four eyes), 1 mg (group 3, four eyes), 0.5 mg (group 4, two eyes), 0.3 mg (group 5, two eyes) or 0.1 mg (group 7, two eyes) of octreotide acetate, two doses of 0.3 mg 1 week apart (group 6, four eyes) or 0.1 mL of balanced salt solution (group 8 [control group], two eyes).
Findings on clinical examination and electroretinography, performed before and 10 days after injection, and on light microscopy.
Cataracts developed in groups 1 and 2. No clinical changes were found in groups 3 to 8. Electroretinography showed various degrees of decrease in the b-wave amplitude in groups 1 and 2; the results were normal in groups 3 to 8. Histologic examination showed macrophage and monocyte infiltration in the vitreous and retina in group 1. No histologic change was seen in the eyes in groups 2 to 8.
Octreotide injected intravitreally is safe at dosages of 1 mg or less.
评估玻璃体内注射奥曲肽的眼毒性。
给体重约2 kg的新西兰白兔分别注射5 mg（第1组，2只眼）、2 mg（第2组，4只眼）、1 mg（第3组，4只眼）、0.5 mg（第4组，2只眼）、0.3 mg（第5组，2只眼）或0.1 mg（第7组，2只眼）的醋酸奥曲肽，或间隔1周分两次注射0.3 mg（第6组，4只眼），或注射0.1 mL平衡盐溶液（第8组[对照组]，2只眼）。
在注射前及注射后10天进行临床检查、视网膜电图检查以及光学显微镜检查。
第1组和第2组出现白内障。第3组至第8组未发现临床变化。视网膜电图显示第1组和第2组的b波振幅有不同程度下降；第3组至第8组结果正常。组织学检查显示第1组的玻璃体和视网膜有巨噬细胞和单核细胞浸润。第2组至第8组的眼未发现组织学改变。
玻璃体内注射奥曲肽剂量在1 mg或以下时是安全的。
